

Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

# **Revision of PRECAUTIONS**

# Lansoprazole/Amoxicillin hydrate/Metronidazole, Rabeprazole sodium/Amoxicillin hydrate/Metronidazole

Aug 6, 2014

## **Non-proprietary Name**

- · Lansoprazole/Amoxicillin hydrate/Metronidazole
- · Rabeprazole sodium/Amoxicillin hydrate/Metronidazole

### Safety measure

Precautions should be revised in the package inserts.

In Clinically significant adverse reactions subsection of Adverse Reactions section, the following texts should be added:

Haemorrhagic colitis:

Haemorrhagic colitis may occur. If symptoms such as abdominal pain, bloody stool, and frequent diarrhea are observed, administration of this drug should be discontinued immediately, and appropriate measures should be taken.

#### NOTE

• This drug is designated to prepare a Drug Guide for Patients.

Pharmaceuticals and Medical Devices Agency Office of Safety I 3·3·2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>